|
KR20240172236A
(ko)
|
2017-01-06 |
2024-12-09 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
EP4087653A4
(en)
*
|
2020-01-10 |
2024-06-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20230111212A1
(en)
*
|
2020-01-10 |
2023-04-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3222816A1
(en)
*
|
2021-06-21 |
2022-12-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
JPWO2022270585A1
(cg-RX-API-DMAC7.html)
|
2021-06-23 |
2022-12-29 |
|
|
|
CA3226301A1
(en)
*
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2023283623A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
US20240318176A1
(en)
*
|
2021-07-09 |
2024-09-26 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
JP2024525613A
(ja)
*
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス,インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
WO2023026994A1
(ja)
*
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート
|
|
CA3230796A1
(en)
|
2021-09-01 |
2023-03-09 |
Biogen Ma Inc. |
Anti-transferrin receptor antibodies and uses thereof
|
|
EP4396351A4
(en)
*
|
2021-09-01 |
2025-12-24 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
|
|
US11833221B2
(en)
*
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
JP2025522433A
(ja)
|
2022-06-15 |
2025-07-15 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
スーパーオキシドジスムターゼ1(SOD1)の発現を阻害するためのRNAi剤、その組成物、及び使用の方法
|
|
WO2025072886A1
(en)
*
|
2023-09-28 |
2025-04-03 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2025076006A2
(en)
*
|
2023-10-02 |
2025-04-10 |
Avidity Biosciences, Inc. |
Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skipping
|
|
WO2025085810A2
(en)
*
|
2023-10-18 |
2025-04-24 |
Sarepta Therapeutics, Inc. |
Antisense oligomers for treatment of centronuclear myopathies
|
|
EP4652282A4
(en)
*
|
2023-11-14 |
2026-06-24 |
Cavalry Biosciences Inc |
Compositions designed to target muscle cells and their uses
|
|
US12527877B2
(en)
|
2024-01-24 |
2026-01-20 |
Arrowhead Pharmaceuticals, Inc. |
Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
|
|
CN118531138B
(zh)
*
|
2024-06-18 |
2025-04-01 |
湖北省农业科学院畜牧兽医研究所 |
猪肉品质和胴体关联的snp及应用
|
|
WO2025262186A2
(en)
*
|
2024-06-20 |
2025-12-26 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Therapeutic oligonucleotides for treating diseases being associated with or caused by a missense, nonsense or in-frame indel mutation
|
|
CN118516348B
(zh)
*
|
2024-07-23 |
2025-01-17 |
深川生物科技(山东)股份公司 |
单链核酸或双链核酸及在制备治疗杜氏肌营养不良的药物中的应用
|
|
WO2026163078A1
(en)
*
|
2025-01-29 |
2026-08-06 |
Novartis Ag |
Compounds targeting dmpk for the treatment of myotonic dystrophy
|